How does InVitria's ExpressTec® platform produce recombinant proteins?

InVitria uses its proprietary ExpressTec® platform — a rice grain–based recombinant expression system — to produce highly pure, consistent proteins without animal- or human-derived components. The proteins are manufactured at an ISO9001:2015 certified facility in Kansas, USA, and the platform is designed for scalable supply, with metric ton capacity and global distribution. This matters if you're sourcing recombinant proteins for cell culture, biomanufacturing, or final formulation and want to avoid serum variability and reduce contamination risk.

What ExpressTec® is

ExpressTec® is InVitria's proprietary expression platform built on rice grain. Instead of using mammalian or other animal-derived expression systems, InVitria expresses recombinant proteins in this non-mammalian system. The result is a suite of recombinant protein products that are completely free of animal or human components.

The platform underpins InVitria's positioning around three attributes it states directly: Recombinant, Scalable, Sustainable.

How the production approach works

Based on InVitria's description, the process follows this logic:

1. Expression in rice grain — the target protein is produced via the ExpressTec® rice grain–based expression platform.
2. No animal or human inputs — because the system is non-mammalian and animal-origin-free, the resulting proteins avoid animal- or human-derived components.
3. Manufacturing at a certified facility — production takes place at an ISO9001:2015 certified facility in Kansas, USA.
4. Scalable output — the platform supports metric ton capacity and global distribution.

The stated outcome is proteins that are highly pure and consistent, which InVitria frames as a way to eliminate serum variability, reduce contamination risk, and improve process consistency.

What this means in practice

If your workflow depends on recombinant proteins, the practical implications InVitria highlights are:

• Animal-origin-free, chemically defined proteins — relevant when you need to avoid blood-derived or animal-derived components.
• Consistent, scalable supply — supported by metric ton capacity and global distribution.
• Reduced contamination risk — a direct consequence of removing animal/human-derived components.
• Proven in regulated products — InVitria states its proteins are used in FDA- and EMA-approved biologics, and that its recombinant proteins are used in over 30 on-market products, including the first FDA-approved vaccine containing rHSA.

Product types produced on the platform

InVitria's catalog of recombinant, animal-origin-free products includes:

These are applied across gene therapy, cell therapy, vaccine production, T-cell immunotherapy, final formulation, medical device, and antibody production.

Where to verify specifics

For product specifications, formats, and application details, InVitria provides a downloadable catalog covering recombinant proteins, cell culture supplements, and blood-free cell culture media. Because formats and specifications vary by product, check the catalog or the relevant product page before selecting a protein for your workflow.